
Phreesia (PHR) Stock
Cloud patient intake software for hospitals and clinics. Here's the price, business snapshot, and what's worth knowing about Phreesia in August 2026.
Phreesia, Inc. (PHR) provides cloud-based patient intake and engagement software for healthcare organisations, aiming to streamline administrative workflows and capture patient data before clinical encounters. The company sells a mix of software subscriptions and transaction-based services to hospitals, physician groups and specialty clinics, which can create recurring revenue and usage-linked income. Investors often watch Phreesia for its exposure to healthcare digitisation, potential scale benefits and data-driven services such as revenue-cycle tools and analytics. Key considerations include competitive dynamics in health IT, the company’s ability to expand payer and provider integrations, and regulatory and privacy requirements that affect patient data handling. As with any technology stock, growth can be uneven and valuation sensitive to execution. This summary is for educational purposes only and not personalised investment advice — investors should assess financials, strategy and risk tolerance before considering any position.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Phreesia's stock with a target price of $29.5, indicating potential growth.
Financial Health
Phreesia Inc. is generating solid cash flow and revenue, indicating a stable financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring Revenue Profile
Subscription and transaction fees give Phreesia predictable revenue streams, though growth depends on provider adoption and usage — performance can vary.
Platform and Data Services
Its platform enables analytics and revenue-cycle add-ons that can lift margins if adopted at scale, but data privacy and integration hurdles are material considerations.
Digitisation Tailwinds
Wider healthcare digitisation and focus on patient experience support demand, though regulatory changes and competitive dynamics can affect outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.